Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial

Intensive Care Med. 2004 Oct;30(10):1891-9. doi: 10.1007/s00134-004-2378-2. Epub 2004 Jul 20.

Abstract

Objective: To determine the efficacy of minocycline and rifampin-impregnated catheters compared to non-impregnated catheters in critically ill patients.

Design: Prospective, randomized, double-blind, controlled, multicenter trial.

Setting: Intensive care units of seven acute-care teaching hospitals in Spain. PATIENTS. Intensive care unit patients requiring triple-lumen central venous catheter for more than 3 days.

Interventions: At catheter insertion, 228 patients were randomized to minocycline and rifampin-impregnated catheters and 237 to non-impregnated catheters. Skin, catheter tip, subcutaneous segment, hub cultures, peripheral blood and infusate cultures were performed at catheter withdrawal. The rate of colonization, catheter-related bloodstream infection (CRBSI) and catheter-related clinical infectious complications (purulence at the insertion site or CRBSI) were assessed.

Measurements and main results: In the intention-to-treat analysis (primary analysis), the episodes per 1000 catheter days of clinical infectious complications decreased from 8.6 to 5.7 (RR =0.67, 95% CI 0.31-1.44), CRBSI from 5.9 to 3.1 (RR =0.53, 95% CI 0.2-1.44) and tip colonization from 24 to 10.4 (RR =0.43, 95% CI 0.26-0.73). Antimicrobial-impregnated catheters were associated with a significant decrease of coagulase-negative staphylococci colonization (RR =0.24, 95% CI 0.13-0.45) and a significant increase of Candida spp. colonization (RR =5.84, 95% CI 1.31-26.1).

Conclusions: The use of antimicrobial-impregnated catheters was associated with a significantly lower rate of coagulase-negative staphylococci colonization and a significant increase in Candida spp. colonization, although a decrease in CRBSI, increase in 30-day survival or reduced length of stay was not observed.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Bacterial Infections / blood
  • Bacterial Infections / epidemiology
  • Bacterial Infections / prevention & control*
  • Blood-Borne Pathogens
  • Catheterization, Central Venous* / adverse effects
  • Catheterization, Central Venous* / instrumentation
  • Catheters, Indwelling / microbiology
  • Critical Illness
  • Cross Infection / blood
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Cross Infection / prevention & control*
  • Double-Blind Method
  • Drug Delivery Systems*
  • Humans
  • Intensive Care Units
  • Minocycline / administration & dosage*
  • Prospective Studies
  • Rifampin / administration & dosage*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Minocycline
  • Rifampin